Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141758 | 0.87 | APLNR (0.65) | MTNR1AMTNR1BHTTALDH1A1GAA | |
| SCHEMBL13647189 | 0.84 | HSD17B10 (0.56) | MTNR1AMTNR1BHSD17B10HTTALDH1A1 | |
| SCHEMBL18183442 | 0.84 | MTNR1B (0.84) | MTNR1AMTNR1B | |
| SCHEMBL8460016 | 0.84 | MTNR1A (0.50) | MTNR1AMTNR1BHSD17B10HTTALDH1A1 | |
| SCHEMBL19625146 | 0.84 | MTNR1A (0.54) | MTNR1AMTNR1B | |
| SCHEMBL20738484 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BALDH1A1GAAHPGD | |
| SCHEMBL13647314 | 0.83 | SHMT2 (0.57) | MTNR1AMTNR1BHSD17B10HTTALDH1A1 | |
| SCHEMBL4856579 | 0.83 | MTNR1A (0.49) | MTNR1AMTNR1BHTTALDH1A1GAA | |
| SCHEMBL20738591 | 0.83 | SETDB1 (0.53) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL8644052 | 0.83 | ALDH1A1 (0.61) | ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATGON (KR) | 2026-03-05 | — | — | US | disclosed |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-12-09 | — | — | US | disclosed |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2024-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061083-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | MTNR1A 1125/4885MTNR1B 1005/4885HSD17B10 2232/4885 |
| US-12491271-B2 | Positron emission tomography radiotracer for diseases associated with translocator protein overexpression, translocator protein-targeting ligand for fluorescence imaging-guided surgery and photodynamic therapy, and production methods therefor | TSPO, FABP7, SLC46A1 | MTNR1A 347/4885MTNR1B 528/4885HSD17B10 1891/4885 |
| US-20240156997-A1 | POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFOR | TSPO, FABP7, SLC46A1 | MTNR1A 347/4885MTNR1B 528/4885HSD17B10 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.